VBI Vaccines Inc. [VBIV] stock prices are up 13.25% to $0.70 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VBIV shares have gain 21.76% over the last week, with a monthly amount glided 18.64%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 2, April 2024, VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform. In a post published today on Yahoo Finance, VBI Vaccines and the Canadian government broaden scope of longstanding collaboration to accelerate development of VBI’s novel, mRNA-launched enveloped virus-like particle vaccine (“MLE”) technology platform.
From an analyst’s perspective:
VBI Vaccines Inc. [NASDAQ: VBIV] stock has seen the most recent analyst activity on November 11, 2022, when Raymond James downgraded its rating to a Outperform and also revised its price target to $2 from $5. On February 25, 2021, Jefferies initiated with a Buy rating and assigned a price target of $7 on the stock. Raymond James upgraded its rating to a Strong Buy and increased its price target to $9 on August 27, 2020. Oppenheimer initiated its recommendation with a Outperform and recommended $9 as its price target on January 16, 2019. Canaccord Genuity started tracking with a Buy rating for this stock on November 01, 2017, and assigned it a price target of $10. In a note dated October 10, 2016, Laidlaw initiated an Buy rating and provided a target price of $6 on this stock.
The stock price of VBI Vaccines Inc. [VBIV] has been fluctuating between $0.45 and $9.54 over the past year. VBI Vaccines Inc. [NASDAQ: VBIV] shares were valued at $0.70 at the most recent close of the market.
Analyzing the VBIV fundamentals
The VBI Vaccines Inc. [NASDAQ:VBIV] reported sales of 8.12M for trailing twelve months, representing a surge of 1989.59%. Gross Profit Margin for this corporation currently stands at -0.59% with Operating Profit Margin at -10.83%, Pretax Profit Margin comes in at -14.03%, and Net Profit Margin reading is -15.04%. To continue investigating profitability, this company’s Return on Assets is posted at -1.21, Equity is -3.54 and Total Capital is -3.73. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6153 points at the first support level, and at 0.5305 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7569, and for the 2nd resistance point, it is at 0.8137.
VBI Vaccines Inc. [VBIV] reported earnings per share of -$1.01 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.14/share, meaning a difference of -$0.87 and a surprise factor of -621.40%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$5.05 per share as compared to estimates of -$2.16 per share, a difference of -$2.89 representing a surprise of -133.80%.
Ratios To Look Out For
It’s worth pointing out that VBI Vaccines Inc. [NASDAQ:VBIV]’s Current Ratio is 0.65. In addition, the Quick Ratio stands at 0.55 and the Cash Ratio stands at 0.46. Considering the valuation of this stock, the price to sales ratio is 2.04, the price to book ratio is 0.82.
Transactions by insiders
Recent insider trading involved GILLIS STEVEN, Director, that happened on Jul 10 ’23 when 0.61 million shares were purchased. 10% Owner, PERCEPTIVE ADVISORS LLC completed a deal on Apr 06 ’23 to sell 4.25 million shares. Meanwhile, 10% Owner PERCEPTIVE ADVISORS LLC sold 1.83 million shares on Apr 05 ’23.
